Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

ClinicalTrials.gov ID: NCT04186845

Public ClinicalTrials.gov record NCT04186845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

Study identification

NCT ID
NCT04186845
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Blue Earth Diagnostics
Industry
Enrollment
391 participants

Conditions and interventions

Interventions

Drug · Diagnostic Test

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 4, 2020 (Actual)
Primary completion
Apr 28, 2021 (Actual)
Completion
Apr 28, 2021 (Actual)
Last update posted
Sep 22, 2025

2020 – 2021

United States locations

U.S. sites
25
U.S. states
13
U.S. cities
24
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233 —
Tower Urology Los Angeles California 90048 —
University of California Irvine Medical Center (UCIMC) Orange California 92868 —
John Wayne Cancer Institute Santa Monica California 90403 —
Emory University Hospital Atlanta Georgia 30322 —
Northside Hospital Austell Georgia 30342 —
Northshore University HealthSystem Evanston Illinois 60201 —
Loyola University Medical Center Maywood Illinois 60153 —
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore Maryland 21287 —
Chesapeake Urology Research Associates Towson Maryland 21204 —
University of Michigan Ann Arbor Ann Arbor Michigan 48109 —
Karmanos Cancer Institute Detroit Michigan 48201 —
Washington University School of Medicine St Louis Missouri 63110 —
Queens Hospital Center (QHC - Queens Cancer Center Jamaica New York 11432 —
Mount Sinai Faculty Practice Associates New York New York 10029 —
Stony Brook University Stony Brook New York 11794 —
Montefiore Hospital The Bronx New York 10461 —
Duke University Medical Center Durham North Carolina 27701 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
Cleveland Clinic Cleveland Ohio 44195 —
MidLantic Urology Philadelphia Pennsylvania 19004 —
MD Anderson Hospital Houston Texas 77054 —
Urology San Antonio San Antonio Texas 78229 —
University of Virginia - Health Science Center Charlottesville Virginia 22908 —
Virginia Oncology Associates Norfolk Virginia 23502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04186845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2025 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04186845 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →